# SANGUINE DIAGNOSTICS AND THERAPEUTICS: Anti-MUC16 humanized antibody combination regimen for targeting metastasis in pancreatic cancer

**Lab Budget Score:** 40/100

| Field | Value |
|---|---|
| Organization | SANGUINE DIAGNOSTICS AND THERAPEUTICS |
| Location | OMAHA, NE |
| Project | Anti-MUC16 humanized antibody combination regimen for targeting metastasis in pancreatic cancer |
| Project number | 1R44CA306744-01A1 |
| Mechanism | R44 |
| Institute | National Cancer Institute |
| Award | $399,999 |
| Awarded | 2026-09-16 |
| Project period | 2026-09-15 to 2027-08-31 |
| UEI | ECGMLSHGH4X6 |

## Why this score
- Award of $399,999.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11408229). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.